Global Esophageal Candidiasis Treatment Market, By Treatment (Diagnosis, Medication, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Esophageal Candidiasis Treatment Market
Global esophageal candidiasis treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.30% in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.
Moreover, continuous public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics also boost up the market growth. Continuous rising prevalence of candidiasis infection and expanding pool of patients suffering from esophageal candidiasis all over the world also boost up the market growth. Increasing new treatment options act as opportunity for the market growth. But, least availability of medical facilities, lack of awareness in developing countries and presence of alternative treatment may hamper the global esophageal candidiasis treatment market.
Esophageal candidiasis is the most common infection and commonly seen in patients suffering from HIV-AIDS or patients suffering with impaired cellular immunity such as hematologic malignancies, immunosuppressive therapy & diabetes mellitus. The symptoms of the esophageal candidiasis are odynophagia, dysphagia, chest pain and many more. It is caused by the yeast known as Candida. The patients, who have infectious esophagitis, are 88% from Candida albicans, 10% are from herpes simplex virus, and 2% are from cytomegalovirus.
The median age of a person with esophageal candidiasis is 55.5 years. Studies have shown the incidence rate of esophageal candidiasis ranging from 0.32 to 5.2% in the general population. In HIV positive patients the prevalence rate is 9.8%. The risk of esophageal candidiasis increases in HIV patients when the CD4 count is less than 200.
This esophageal candidiasis treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Esophageal Candidiasis Treatment Market Scope and Market Size
The esophageal candidiasis treatment market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment, the esophageal candidiasis treatment market is segmented into diagnosis, medication and others. Diagnosis segment further divided into imaging test, histopathology test and others. Medication segment further divided into antifungal such as fluconazole, micafungin, itraconazole, voriconazole, amphotericin B deoxycholate, posaconazole and others.
- On the basis of route of administartion, the esophageal candidiasis treatment market is segmented into oral and parenteral.
- On the basis of end-users, the esophageal candidiasis treatment market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the esophageal candidiasis treatment market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Esophageal Candidiasis Treatment Market Country Level Analysis
Esophageal candidiasis treatment market is analysed and market size information is provided by country, type, treatment, population, end-users and distribution channel as referenced above.
The countries covered in the esophageal candidiasis treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to the presence of high healthcare expenditure and increased clinical studies for the treatment. Europe accounts second largest market share because of well-established healthcare facilities and appropriate reimbursement policies. Asia-Pacific is expected to account for the largest market share over coming years for the esophageal candidiasis treatment market due to constant rise in the incidence of esophageal candidiasis treatment and rising demand for cost-efficient therapeutics.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Esophageal candidiasis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Esophageal Candidiasis Treatment Market Share Analysis
Esophageal candidiasis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to esophageal candidiasis treatment market.
The major players covered in the esophageal candidiasis treatment market are GlaxoSmithKline plc, Pfizer Inc., Mylan N.V., Macleods Pharmaceuticals, Cadila Pharmaceuticals, Johnson & Johnson Services, Inc. Teva Pharmaceutical Industries Ltd., Bayer AG, Sun Pharmaceutical Industries Ltd., Perrigo Pharmaceutical plc., Sandoz AG, Hikma Pharmaceutical PLC among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
